Edgewise Therapeutics, Inc. EWTX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -34.2%+0.2pp | -34.4%-4.3pp | -30.1%-8.3pp | -21.8%— | |
| Return on invested capital | -43.1%+5.0pp | -48.1%-7.8pp | -40.3%— | —— | |
| Liquidity | |||||
| Current ratio | 19.9×-0.1× | 19.9×+0.4× | 19.5×-2.0× | 21.5×-5.4× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Per Share | |||||
| Book value per share | $5.07+2.1% | $4.97-0.7% | $5.00-22.7% | $6.47-11.5% | |
| Valuation | |||||
| Market capitalization | $2.63B+3.9% | $2.53B+257% | $708.64M+25.4% | $565.29M-25.3% | |
| Price / book | 5×-0.5× | 5.5×+3.3× | 2.2×+0.6× | 1.6×-1.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Edgewise Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Edgewise Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.